These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9514052)

  • 1. Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide.
    Campbell MJ; Dawson M; Koeffler HP
    Br J Cancer; 1998 Mar; 77(5):739-44. PubMed ID: 9514052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis.
    Shen JC; Wang TT; Chang S; Hursting SD
    Mol Carcinog; 1999 Mar; 24(3):160-8. PubMed ID: 10204800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase A RIalpha antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation.
    Cho YS; Kim MK; Tan L; Srivastava R; Agrawal S; Cho-Chung YS
    Clin Cancer Res; 2002 Feb; 8(2):607-14. PubMed ID: 11839683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H; Tolcher A; Gleave ME
    J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
    Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
    Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents.
    Shi XB; Gumerlock PH; Muenzer JT; deVere White RW
    Cancer Biother Radiopharm; 2001 Oct; 16(5):421-9. PubMed ID: 11776759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting apoptosis in prostate cancer.
    DiPaola RS; Patel J; Rafi MM
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):509-24. PubMed ID: 11525294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Dandekar DS; Lokeshwar BL
    Clin Cancer Res; 2004 Dec; 10(23):8037-47. PubMed ID: 15585639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins.
    Lytle RA; Jiang Z; Zheng X; Higashikubo R; Rich KM
    J Neurooncol; 2005 Sep; 74(3):225-32. PubMed ID: 16187019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
    Rubenstein M; Tsui P; Guinan P
    Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
    Mercatante DR; Mohler JL; Kole R
    J Biol Chem; 2002 Dec; 277(51):49374-82. PubMed ID: 12381725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of apoptosis by endogenous Bcl-xL expression in MKN-45 human gastric cancer cells.
    Kondo S; Shinomura Y; Kanayama S; Higashimoto Y; Kiyohara T; Zushi S; Kitamura S; Ueyama H; Matsuzawa Y
    Oncogene; 1998 Nov; 17(20):2585-91. PubMed ID: 9840921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4.
    Hayashi K; Goodison S; Urquidi V; Tarin D; Lotan R; Tahara E
    Int J Oncol; 2003 Mar; 22(3):623-9. PubMed ID: 12579317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.
    Dorai T; Goluboff ET; Olsson CA; Buttyan R
    Anticancer Res; 1997; 17(5A):3307-12. PubMed ID: 9413164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.